Workflow
ORIC® Pharmaceuticals Expands Leadership Team with the Appointment of Kevin Brodbeck as Chief Technical Officer
OricOric(US:ORIC) Globenewswire·2025-08-18 20:05

Core Insights - ORIC Pharmaceuticals has appointed Kevin Brodbeck, PhD, as the Chief Technical Officer (CTO), a newly established role aimed at enhancing technical operations as the company advances its clinical programs into late-stage development [1][2] - The appointment of Dr. Brodbeck is strategic as ORIC prepares for potential Phase 3 trials for its product candidates ORIC-944 and enozertinib (ORIC-114) in 2026, highlighting the importance of Chemistry, Manufacturing, and Controls (CMC) and Technical Operations [1][2] Company Overview - ORIC Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing treatments that overcome resistance in cancer [3] - The company's clinical stage product candidates include ORIC-944, an allosteric inhibitor targeting prostate cancer, and enozertinib (ORIC-114), which targets multiple genetically defined cancers [3] Leadership Background - Dr. Brodbeck has over 25 years of experience in technical operations, quality assurance, and regulatory activities across various pharmaceutical products [1][2] - Prior to joining ORIC, Dr. Brodbeck held significant roles at Deciphera Pharmaceuticals and Nektar Therapeutics, where he led various development programs and established strategic partnerships [2]